Patents by Inventor Richard Anthony Whitaker

Richard Anthony Whitaker has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Potent and selective inhibitors of hepatitis C virus
    Patent number: 9932326
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.
    Type: Grant
    Filed: November 10, 2015
    Date of Patent: April 3, 2018
    Assignees: Cocrystal Pharma, LLC, Emory University
    Inventors: Steven J. Coats, Franck Amblard, Hongwang Zhang, Longhu Zhou, Richard Anthony Whitaker, Tamara Rosario McBrayer, Raymond F. Schinazi, Junxing Shi
  • Potent and selective inhibitors of hepatitis C virus
    Patent number: 9926295
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.
    Type: Grant
    Filed: April 15, 2015
    Date of Patent: March 27, 2018
    Assignees: Cocrystal Pharma, Inc., Emory University
    Inventors: Steven J. Coats, Richard Anthony Whitaker, Tamara Rosario McBrayer, Junxing Shi, Franck Amblard, Hongwang Zhang, Longhu Zhou, Raymond F. Schinazi
  • POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS
    Publication number: 20170029407
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.
    Type: Application
    Filed: April 15, 2016
    Publication date: February 2, 2017
    Inventors: Steven J. Coats, Richard Anthony Whitaker, Tamara Rosario McBrayer, Junxing Shi, Franck Amblard, Hongwang Zhang, Longhu Zhou, Raymond F. Schinazi
  • POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS
    Publication number: 20160068518
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.
    Type: Application
    Filed: November 10, 2015
    Publication date: March 10, 2016
    Inventors: Steven J. Coats, Franck Amblard, Hongwang Zhang, Longhu Zhou, Richard Anthony Whitaker, Tamara Rosario McBrayer, Raymond F. Schinazi, Junxing Shi
  • Potent and selective inhibitors of hepatitis C virus
    Patent number: 9181227
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.
    Type: Grant
    Filed: August 8, 2014
    Date of Patent: November 10, 2015
    Assignees: Cocrystal Pharma, Inc., Emory University
    Inventors: Steven J. Coats, Franck Amblard, Hongwang Zhang, Longhu Zhou, Richard Anthony Whitaker, Tamara Rosario McBrayer, Raymond F. Schinazi, Junxing Shi
  • POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS
    Publication number: 20140350016
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.
    Type: Application
    Filed: August 8, 2014
    Publication date: November 27, 2014
    Inventors: Steven J. Coats, Franck Amblard, Hongwang Zhang, Longhu Zhou, Richard Anthony Whitaker, Tamara Rosario McBrayer, Raymond F. Schinazi, Junxing Shi
  • Potent and selective inhibitors of hepatitis C virus
    Patent number: 8859595
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.
    Type: Grant
    Filed: August 26, 2011
    Date of Patent: October 14, 2014
    Assignees: RFS Pharma, LLC, Emory University
    Inventors: Steven J. Coats, Franck Amblard, Hongwang Zhang, Longhu Zhou, Richard Anthony Whitaker, Tamara Rosario McBrayer, Raymond F. Schinazi, Junxing Shi
  • 3?-azido purine nucleotide prodrugs for treatment of viral infections
    Patent number: 8815829
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HIV, and HBV, in human patients or other animal hosts. The compounds are 3?-azido-2?,3?-dideoxy purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1 and HBV.
    Type: Grant
    Filed: December 9, 2009
    Date of Patent: August 26, 2014
    Assignees: RFS Pharma, LLC, Emory University, University of Pittsburgh—of the Commonwealth System of Higher Education
    Inventors: Raymond F. Schinazi, John W. Mellors, Nicolas Paul Sluis-Cremer, Steven J. Coats, Richard Anthony Whitaker, Brian David Herman, Jong Hyun Cho, Longhu Zhou, Hongwang Zhang
  • Specific HCV NS3 protease inhibitors
    Patent number: 8729014
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HCV in human patients or other animal hosts.
    Type: Grant
    Filed: October 28, 2011
    Date of Patent: May 20, 2014
    Assignees: RFS Pharma, LLC, Genoscience
    Inventors: Jerome Courcambeck, Philippe Halfon, Mourad Bouzidi, Steven J. Coats, Richard Anthony Whitaker
  • POTENT AND SELECTIVE INHIBITORS OF HEPATITIS C VIRUS
    Publication number: 20130210774
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing hepatitis C virus (HCV) infection in human subjects or other animal hosts. The compounds are as also pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof as pharmaceutical compositions and methods for treatment or prevention of HCV infection.
    Type: Application
    Filed: August 26, 2011
    Publication date: August 15, 2013
    Applicants: EMORY UNIVERSITY, RFS PHARMA, LLC
    Inventors: Steven J. Coats, Franck Amblard, Hongwang Zhang, Longhu Zhou, Richard Anthony Whitaker, Tamara Rosario McBrayer, Raymond F. Schinazi, Junxing Shi
  • Nucleoside derivatives for treatment of infections, including Norovirus infections
    Patent number: 8415321
    Abstract: A method and composition for treating a host infected with a Caliciviridae virus, such as a Norovirus, comprising administering an effective treatment amount of a described modified nucleoside or a pharmaceutically acceptable salt thereof, is provided.
    Type: Grant
    Filed: April 9, 2009
    Date of Patent: April 9, 2013
    Inventors: Raymond F. Schinazi, Richard Anthony Whitaker, Tamara Rosario McBrayer, Steven J. Coats
  • 3'-AZIDO PURINE NUCLEOTIDE PRODRUGS FOR TREATMENT OF VIRAL INFECTIONS
    Publication number: 20120135951
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HIV, and HBV, in human patients or other animal hosts. The compounds are 3?-azido-2?,3?-dideoxy purine monophosphates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1 and HBV.
    Type: Application
    Filed: December 9, 2009
    Publication date: May 31, 2012
    Inventors: Raymond F. Schinazi, Ph.D., John W. Mellors, Nicolas Paul Sluis-Cremer, Steven J. Coats, Ph.D., Richard Anthony Whitaker, Brian David Herman, Jong Hyun Cho, Longhu Zhou, Hongwang Zhang
  • NOVEL SPECIFIC HCV NS3 PROTEASE INHIBITORS
    Publication number: 20120129765
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HCV in human patients or other animal hosts.
    Type: Application
    Filed: October 28, 2011
    Publication date: May 24, 2012
    Applicants: GENOSCIENCE, RFS Pharma, LLC
    Inventors: Jerome Courcambeck, Philippe Halfon, Mourad Bouzidi, Steven J. Coats, Richard Anthony Whitaker
  • AZIDO PURINE NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTIONS
    Publication number: 20100279969
    Abstract: The present invention is directed to compounds, compositions and methods for treating or preventing viral infections, in particular, HIV, HBV, and HCV, in human patients or other animal hosts. The compounds are 3?-azido-2?,3?-dideoxy purine nucleosides or phosphonates, and pharmaceutically acceptable, salts, prodrugs, and other derivatives thereof. In particular, the compounds show potent antiviral activity against HIV-1 resistance mutants including HIV-1K65R, HTV-1K70E, HIV-1L74V, HIV-1M184V, HIV-1Q151M and inhibitory activity against HIV-1 RT harboring TAMS or insertion mutations including HIV-1AZT3, HIV-1AZT7, HIV-1AZT9, HIV-1Q151M, or HIV-169insertion. In one embodiment, the compounds are 3?-azido-ddA, 3?-azido-ddG, or combinations thereof, administered with one or more additional antiviral agents that select for TAM mutations and/or the M 184V mutation, along with a pharmaceutically acceptable carrier.
    Type: Application
    Filed: May 14, 2008
    Publication date: November 4, 2010
    Applicants: RFS PHARMA, LLC, EMORY UNIVERSITY, UNIVERSITY OF PITTSBURGH
    Inventors: Raymond F. Schinazi, John W. Mellors, Nicolas Paul Sluis-Cremer, Frank Amblard, Steven J. Coats, Junxing Shi, Richard Anthony Whitaker
  • NUCLEOSIDE DERIVATIVES FOR TREATMENT OF CALICIVIRIDAE INFECTIONS, INCLUDING NOROVIRUS INFECTIONS
    Publication number: 20090280084
    Abstract: A method and composition for treating a host infected with a Caliciviridae virus, such as a Norovirus, comprising administering an effective treatment amount of a described modified nucleoside or a pharmaceutically acceptable salt thereof, is provided.
    Type: Application
    Filed: April 9, 2009
    Publication date: November 12, 2009
    Inventors: Raymond F. Schinazi, Richard Anthony Whitaker, Tamara Rosario McBrayer, Steven J. Coats